Independent, source-cited explainers on choosing pharma & wellness products, fact-checked against public health authorities.
The GLP-1 field is moving fast: the first oral GLP-1 pill (orforglipron / Foundayo) was FDA-approved in April 2026, while retatrutide and CagriSema are still in late-stage trials. Here is what each one is, where it stands, and how it compares to the approved options you can get today.
pharmaranks Editorial · Jun 28, 2026
ResearchAI assistants say "sterile injectables account for a large share" of recalls but can't rank drug classes. We quantified it from FDA enforcement data.
pharmaranks Editorial · Jun 19, 2026
ResearchThe FDA doesn't publish a leaderboard of the most-recalled drugs — so we built one. Here are the prescription products with the most FDA recall events, by application.
pharmaranks Editorial · Jun 19, 2026
ResearchWe ranked 46 drug manufacturers by their FDA recall-safety score. High-volume generic and injectable makers lead the recall record — here's the full data.
pharmaranks Editorial · Jun 18, 2026
SafetyRecalls are an objective signal of a manufacturing or safety problem — here's how we use them in our ratings.
pharmaranks Editorial · Jun 7, 2026
EducationGenerics must match the brand's active ingredient and bioequivalence — here's what can differ, and what doesn't.
pharmaranks Editorial · Jun 7, 2026
MethodologyA plain-language look at the data and formula behind every pharmaranks score.
pharmaranks Editorial · Jun 7, 2026